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Abstract
Background: S1P3 is a lipid-activated G protein-couple receptor (GPCR) that has been implicated in the pathological
processes of a number of diseases, including sepsis and cancer. Currently, there are no available high-affinity, subtype-
selective drug compounds that can block activation of S1P3. We have developed a monoclonal antibody (7H9) that
specifically recognizes S1P3 and acts as a functional antagonist.
Methodology/Principal Findings: Specific binding of 7H9 was demonstrated by immunocytochemistry using cells that
over-express individual members of the S1P receptor family. We show, in vitro, that 7H9 can inhibit the activation of S1P3-
mediated cellular processes, including arrestin translocation, receptor internalization, adenylate cyclase inhibiton, and
calcium mobilization. We also demonstrate that 7H9 blocks activation of S1P3 in vivo, 1) by preventing lethality due to
systemic inflammation, and 2) by altering the progression of breast tumor xenografts.
Conclusions/Significance: We have developed the first-reported monoclonal antibody that selectively recognizes a lipid-
activated GPCR and blocks functional activity. In addition to serving as a lead drug compound for the treatment of sepsis
and breast cancer, it also provides proof of concept for the generation of novel GPCR-specific therapeutic antibodies.
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Introduction
The use of monoclonal antibodies (mAbs) to antagonize
transembrane receptors has met with tremendous clinical and
commercial success over the course of the past decade. The success
of antibody drugs is based on their exquisite specificity and affinity,
which are essential components of targeted molecular therapy.
With 23 antibody drugs currently approved for clinical use and
annual sales in the tens of billions of dollars [1], these biologics are
being used for a wide range of indications such as inflammatory
diseases, autoimmune diseases, stroke, and heart disease, but the
greatest therapeutic antibody success stories involve the treatment
of cancer. Examples of some the most effective and widely used,
anti-cancer therapeutic antibody drugs include trastuzumab
(HerceptinH, a HER2 inhibitor), bevacizumab (AvastinH, a VEGF
inhibitor), and panitumumab (Vectibix
TM, an EGFR inhibitor).
Sphingosine 1-phosphate (S1P) is a lipid signaling molecule
(Figure 1) that is present in serum at biologically relevant
concentrations (high nanomolar range). S1P is generated by the
phosphorylation of sphingosine by sphingosine kinase in the final
step of a highly conserved metabolic pathway [2]. Although there
have been reports of some intracellular roles of S1P [3–5], the
majority of its effects are mediated by a family of five known S1P-
selective G protein-coupled receptors (GPCRs). These receptors
belong to a GPCR subfamily (formerly known as the ‘‘Edg’’
receptors) whose members are activated by S1P (S1P1–5) or the
structurally similar lipid, lysophosphatidic acid (LPA; LPA1–3).
They couple to a number of G proteins and downstream effectors
to elicit a variety of responses in almost every known cell type. The
responses vary among cell types depending on the expression
profile of the receptors and effectors, but notably include
proliferation, survival, and cytoskeletal rearrangement (reviewed
in: [6–9]).
Previous studies are consistent with a pro-tumorigenic role of
S1P. S1P is known to increase the proliferation, survival, motility,
and invasiveness of breast tumor cells [10–13]. In addition, the
known involvement of S1P signaling in the processes of
angiogenesis and vascular maturation underscores the importance
of this pathway in cancer progression [14,15]. The tumor-
promoting effect of S1P is directly supported by the observation
that overexpression of sphingosine kinase in MCF-7 cells promotes
tumorigenesis and tumor vascularization in a nude mouse model
[10]. Furthermore, it has been demonstrated that neutralization of
S1P has a potent tumor-suppressive effect [16], an approach that is
currently under clinical investigation.
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likely to be largely mediated by the activation of cognate receptor
subtype S1P3. S1P3 is the most highly expressed S1P receptor in
BCCs [17,18], is known to promote cell migration [19–21] and
EGF responsivity [11,12,18,22,23], and may mediate the pro-
liferative effects of estrogen [24]. In addition to the direct effects
that S1P3 have on BCCs, S1P3 also mediates angiogenesis [25–
31], thus promoting tumor growth by increasing vascularity. A
recent study provided evidence for the clinical importance of S1P3
by showing that expression of S1P3 in breast tumors positively
correlates with decreased tamoxifen sensitivity and decreased
patient survival [32].
In addition to promoting tumor development, activation of
S1P3 is also involved in the pathology of inflammatory responses.
This is most clearly illustrated by the fact that mice specifically
lacking S1P3 are resistant to the effects of the bacterial endotoxin
lipopolysaccharide (LPS) [33]. There is near complete attenuation
of inflammatory cytokine release in S1P3
-/- mice following LPS
challenge. Most importantly, when LPS is administered at a dose
that is lethal to 90% of wild-type mice, more than 80% of S1P3
knockouts survive. The protective effect of S1P3 loss-of-function is
likely due to the roles of S1P3 in both immune cells and endothelial
cells. S1P3 has been shown to mediate pro-inflammatory responses
in a number of pathological conditions [34]. This is mediated by
multiple immune cell types including dendritic cells [35,36].
Moreover, it is known that activation of S1P3 on endothelial cells
causes the disruption of tight junctions and an increase in vascular
permeability that results in hemodynamic instability during septic
shock [37–40]. This pathological activation of S1P3 occurs
downstream of thrombin-induced innate immune responses to
cause an amplification of cytokine release and inflammation and
a loss of vascular integrity [33,41].
Considering these known pathological roles, we reasoned that
specific antagonism of S1P3 would be likely to provide effective
protection against breast tumor development and acute systemic
inflammation. Since the structural similarities among the ‘‘Edg’’
family of receptors provide significant challenges to the generation
of subtype-selective small molecule inhibitors, we elected to pursue
the development of a blocking monoclonal antibody. While this
approach itself has unique challenges for GPCR targets, we have
developed one S1P3-blocking mAb: 7H9. Here we demonstrate
the specificity and efficacy of 7H9 and evaluate its therapeutic
potential in animal models for sepsis and breast cancer.
Results
7H9 Specifically Binds S1P3
Monoclonal antibody 7H9 was evaluated for specificity to S1P3
by immunocytochemistry (Figure 2). S1P3 is a member of the
highly conserved ‘‘Edg’’ family of GPCRs. HEK293 cells were
transfected with expression constructs for each of 7 different
‘‘Edg’’ family receptors, then fixed and incubated with purified
7H9 antibody (1 mg/ml). Specific binding to S1P3-expressing cells
was apparent by epifluorescence, while binding to the remaining
‘‘Edg’’ receptors was undetectable.
7H9 Blocks Activation of S1P3
Since stimulation of S1P3 results in the activation of multiple
downstream processes, we evaluated 7H9 for its ability to inhibit
a number of distinct S1P3-mediated events.
Arrestin translocation. The signal amplitude of canonical
GPCRs is limited by the arrestin family of regulatory proteins.
Upon activation of GPCRs, cytosolic arrestin rapidly binds the
receptor, stimulating receptor phosphorylation and subsequent
clathrin-dependent internalization of the protein complex into
intracellular endosomal vesicles. Vesicular localization of arrestin
is indicative of GPCR activation. This can be visualized with the
use of fluorescently labeled arrestin constructs [42]. To determine
if 7H9 could inhibit S1P3-mediated arrestin translocation, we co-
transfected HEK293 cells with epitope-tagged S1P3 and b-
arrestin-EGFP (Figure 3A-D). EGFP labeling was diffuse
throughout the cytoplasm of unstimulated cells (Figure 3A), but
accumulated into distinct puncta 5 minutes after stimulation with
1mM S1P (Figure 3B). This subcellular redistribution was almost
completely blocked by pre-incubation of cells with 7H9 (Figure 3C-
D).
Receptor internalization. S1P3, like most canonical
GPCRs, is rapidly internalized into cytoplasmic vesicles upon
activation [43]. We investigated whether ligand-dependent
internalization of S1P3 could be blocked by 7H9 (Figure 3E-H).
RH7777 cells were transfected with epitope-tagged S1P3
constructs, stimulated with 1mM S1P for 15 minutes, fixed, and
evaluated by immunocytochemistry. In unstimulated cells, S1P3 is
largely localized to the plasma membrane (Figure 3E). After
exposure to S1P, labeling becomes punctate and accumulates in
the cytoplasm (Figure 3F). This process is dramatically reduced by
pre-treatment with 7H9 (Figure 3G-H).
Calcium mobilization. S1P3 is a Gaq-coupled GPCR and,
upon stimulation with S1P, causes an increase in cytoplasmic Ca
2+
concentration due to a release of intracellular Ca
2+ stores [44,45].
We investigated whether S1P3-dependent calcium release could be
Figure 1. S1P signaling. S1P is an extracellular signaling molecule,
generated by the phosphorylation of sphingosine, that exerts a variety
of effects on a family of 5 cognate GPCRs.
doi:10.1371/journal.pone.0035129.g001
S1P3-Blocking Antibody
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S1P3-EGFP fusion constructs, stimulated with S1P, and evaluated
for [Cai
2+] with calcium indicator dye fura-2. S1P3-expressing cells
demonstrated a robust increase in [Cai
2+] upon exposure to
100 nM S1P, while S1P3-negative cells in the same culture showed
no response. When cells were pre-incubated with conditioned
media from 7H9 hybridoma cultures, S1P was unable to elicit the
release of Cai
2+ until very high, non-physiological concentrations
were applied.
Adenylate cyclase (AC) inhibition. S1P3 also couples to
Gai, and consequently causes the inhibition of AC [45,46]. This
results in a reduction of intracellular cyclic adenosine
monophosphate (cAMP). We investigated whether 7H9 could
block S1P3-mediated Gai signaling by measuring S1P-dependent
changes in intracellular cAMP (Figure 3J). Stimulation of S1P3-
expressing cells with 100 nM S1P resulted in a 35% decrease in
intracellular [cAMP]. This effect was partially inhibited by pre-
treatment with low concentrations of 7H9, and completely blocked
at 10 mg/ml.
7H9 Ameliorates Systemic Inflammation In Vivo
Recent studies in mice demonstrated that deletion of the gene
encoding S1P3 conferred resistance to the systemic inflammatory
response induced by LPS, and afforded marked protection against
the resulting lethality characteristic of disseminated intravascular
coagulation (DIC) [33,41]. We expected that similar protection
would be obtained by antagonizing S1P3 in vivo with the
administration of 7H9 (Figure 4). Mice were pre-treated with
vehicle, non-specific mouse IgG, or 7H9; then were treated with
LPS at the reported LD90 dose [33]. Consistent with previous
studies, 9 out of 10 mice (90%) died within 4 days of LPS
administration in both control groups. However, mice pre-treated
with 7H9 were significantly protected, with only 2 of 10 mice
(20%) succumbing to systemic inflammation.
7H9 Inhibits the Development of Breast Tumor
Xenografts
Since activation of S1P3 is known to contribute to the
development and aggressiveness of breast tumors, we investi-
gated whether antagonism of S1P3 with 7H9 could inhibit the
progression of human breast tumor xenografts in mice (Figure 5).
Solid tumors were established by subcutaneous implantation of
MCF7 cells in Foxn1
Nu/Nu mice using standard techniques [47–
49]. When tumors reached ,200 mm
3 by caliper measurement,
mice were randomized into 2 groups and treated with normal
mouse IgG or 7H9 (1 mg/kg, i.p., QOD), resulting in the stable
accumulation of 7H9 in the serum at concentrations that were
effective in vitro (Figure S1). After approximately 3 weeks of
treatment, tumors in the 7H9 treatment group, on average,
demonstrated a detectable decrease in the rate of development
relative to the normal IgG control group (Figure 5A). This
difference continued to broaden over the next few weeks but fell
short of statistical significance (p=0.16) when the experiment
was terminated on day 50. Interestingly, however, upon
histological examination we noticed a visible increase in the
‘‘necrotic’’ regions of the 7H9-treated tumors (Figure 5B-C).
Quantification revealed that this was a statistically significant, 4-
fold increase (Figure 5D).
Discussion
While the use of therapeutic mAbs has achieved remarkable
clinical success, the application of this technology to GPCR
drug targets has been lagging, due primarily to the difficulty in
generating selective antibodies for critical motifs in these
complex, membrane spanning proteins. This is particularly
problematic for the many GPCRs with lipid ligands, which
typically have inaccessible transmembrane binding pockets.
Here, we describe the generation of the first-reported mAb
that selectively binds a lipid-activated GPCR, and blocks
functional activity.
Figure 2. mAb 7H9 specifically recognizes S1P3. HEK293 cells were transfected with expression constructs for all closely related ‘‘Edg’’ family
GPCRs (green), fixed, incubated with purified 7H9 (1 mg/ml), and visualized with a Cy3-conjugated secondary antibody (red). 7H9 specifically
recognizes cells expressing S1P3, but not its closest homologs.
doi:10.1371/journal.pone.0035129.g002
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35129Figure 3. 7H9 blocks activation of S1P3. (A-D) 7H9 blocks S1P3-mediated arrestin translocation. b-arrestin (green) is cytosolic in quiescent cells
and appears as diffuse labeling (A). Following stimulation with 1 mM S1P (B), arrestin translocates to the plasma membrane and is rapidly internalized
into intracellular vesicles (arrows). In contrast, when cells are pre-treated with 1 mg/ml 7H9 arrestin localization is diffuse and cytoplasmic in both the
absence (C) and presence (D) of 1 mM S1P. (E-H) 7H9 blocks S1P-dependent internalization of S1P3. Epitope-tagged S1P3 is normally abundant on the
S1P3-Blocking Antibody
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generation of an antibody that would bind an extracellular loop
that formed the opening of the ligand binding pocket, thus
preventing ligand-receptor interaction by steric hindrance. This
is consistent with the results of the calcium assay (Figure 3I) in
which normal, physiological concentrations of S1P had no
effect, but unnaturally high concentrations of S1P (,10-fold
higher than normal serum levels) could overcome the inhibition.
While this likely plays a role in the blocking effect of 7H9, the
results of the functional assays suggest that the mechanism of
action is more complex. Specifically, 7H9 at a concentration of
1 mg/ml (,7 nM) provided efficient antagonism in arrestin,
internalization, and calcium assays (Figure 3A-I), but a higher
concentration was required for complete inhibition of the cAMP
response (Figure 3J). While this may simply be the result of
variation between experimental systems, it is possible that 7H9
acts as a somewhat biased antagonist, for example, by altering
the confirmation of S1P3 in a way that decreases its affinity for
Gaq to a greater extent than that of Gai. Additional functional
studies with greater quantitative resolution have been planned
to distinguish between these possibilities.
While the functional studies provide an initial demonstration of
S1P3 antagonism, the best evidence for efficacy was provided by
the in vivo studies. Notably, administration of 7H9 faithfully
phenocopied the genetic null S1pr3
-/- mouse in the LPS challenge,
using the discrete and unambiguous readout of animal survival
(Figure 4). While the effect of 7H9 in the xenografts was less
discrete, there was a trend toward inhibition of tumor growth with
7H9 administration (Figure 5A). The fact that this did not reach
statistical significance may be due to a number of factors. We
expect the direct effect of S1P3 antagonism to be growth-inhibitory
rather than cytotoxic, therefore, the timeframe of this model may
be too short before significance was reached. After 50 days, the
tumors reached a mass that necessitated euthanasia. Alternatively,
the extent of the tumor-suppressive effect of 7H9 may not have
been completely represented by measurement of tumor volume
alone. Indeed, this is supported by the histological analysis of the
tumors (Figure 5B-D). As was previously reported, disruption of
S1P signaling causes an increase in necrotic lesions in tumor
xenografts [16], likely due to decreased tumor angiogenesis.
The recent FDA approval of an S1P receptor-modulating drug
for the treatment of multiple sclerosis [50] has brought a great deal
of attention to this sub-class of GPCRs in the context of drug
development. Significant evidence supports the idea that specific
antagonism of S1P3 should be highly effective in treating a number
of diseases including sepsis [33,41], and breast cancer [32]. The
interaction between S1P3 and estrogen signaling suggests that such
a treatment would be particularly effective as co-therapy with
tamoxifen for the treatment of breast cancer [32,51]. This is
consistent with our preliminary observations and is the subject of
ongoing study. Our initial pilot study shows that 7H9 may
enhance the effect of tamoxifen treatment (Figure S2). While there
plasma membrane (E, arrows), but is internalized into intracellular vesicles (arrowheads) upon stimulation with 1 mM S1P (F). Following pre-treatment
of cells with 7H9, S1P3 remains localized to the plasma membrane in the absence (G) or presence (H) of 1 mM S1P. (I) 7H9 blocks S1P3-dependent
calcium mobilization. S1P3-expressing cells exhibited increased intracellular [Ca
2+] upon stimulation with 100 nM S1P (blue, antibody control). Cells
within the same culture that did not express S1P3-EGFP (green, receptor control) showed no change in [Cai
2+]. Similarly, cells expressing S1P3 that
were pre-treated with 7H9 (red, 7H9) also showed no response to 100 nM and 1 mM S1P, but gave a partial response at 5 mM. (J) 7H9 blocks S1P3-
dependent inhibition of AC. cAMP was measured in S1P3-expressing cells by ELISA and normalized to controls. The graph represents the change in
cAMP content from unstimulated cells, relative to the change observed in stimulated cells with no 7H9 pre-treatment. *p,0.05, **p,0.01. Error bars
= S.E.M.
doi:10.1371/journal.pone.0035129.g003
Figure 4. 7H9 prevents lethality caused by LPS administration.
Survival curve of mice treated with LPS (8 mg/kg, i.p.) on day 0. Mice
were pre-treated with vehicle (PBS), IgG (normal mouse IgG), or 7H9.
doi:10.1371/journal.pone.0035129.g004
Figure 5. 7H9 inhibits development of breast tumor xeno-
grafts. (A) Volumes of subcutaneous MCF7 tumors in nude mice were
determined by caliper measurement. (B-C) Photomicrographs showing
H&E stained tumors from IgG control (B) and 7H9-treated (C) mice. (D)
Volumes of ‘‘necrotic’’ regions were determined by measuring their
cross-sectional areas relative to total area of section. *p,0.05.
doi:10.1371/journal.pone.0035129.g005
S1P3-Blocking Antibody
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tumor volume (Figure S2A), the addition of 7H9 resulted in a further
decrease in the number of mitotic cells in the tumor relative to
tamoxifen alone (Figure S2B). Furthermore, there is also a trend
toward increased tumor necrosis with combination therapy (Figure
S2C). The fact that this parameter did not reach statistical
significance is likely due to the small cohort size (N=3) and awaits
validation.
Since 7H9 is the only known high-affinity, S1P3-selective
antagonist, this mAb is a viable candidate for development as
a lead drug compound. It is also unlikely to be associated with
significant adverse side effects. This is based on 3 lines of evidence:
1) Mice treated with 7H9 in this study exhibited no gross signs of
toxicity, 2) S1P3 knockout mice are phenotypically indistinguish-
able from wild-type littermates [46], and 3) FTY720, a functional
antagonist for multiple S1P receptors including S1P3, is well-
tolerated in humans [52,53]. Interestingly, administration of
FTY720 has been shown to inhibit tumor growth and angiogenesis
in vivo [54,55], however, this compound acts as a potent
immunomodulator through its action on S1P1. While this effect
contributes to its efficacy in the treatment of multiple sclerosis, it is
highly undesirable in cancer patients for which intact immune
surveillance acts to prevent the development of metastatic lesions.
The identification of 7H9 demonstrates that we have developed
a technology that is capable of generating specific blocking
antibodies for an important but problematic class of GPCR drug
targets. We are currently pursuing the development of mAbs for
additional lipid-activated GPCRs to show that this approach may
be generalized to multiple high-value targets.
Materials and Methods
Ethics Statement
Animal protocols were approved by the Institutional Animal
Care and Use Committee at San Diego State University (protocol
#: 10-01-00H and 11-02-003H) and conform to National
Institutes of Health guidelines and public law. All efforts were
made to minimize suffering.
Reagents
Sphingosine-1-phosphate, D-erythro (S1P, BML-SL140-0001,
Enzo Life Sciences, Inc, Farmingdale, NY, USA) was maintained
as a 1mM stock solution in methanol and stabilized by diluting
1:10 with 10% fatty acid-free bovine serum albumin (BSA) before
making final working concentrations by diluting with Dulbecco’s
modified Eagle medium (DMEM).
Generation of 7H9
S1P3-blocking antibody 7H9 was generated by immunizing
mice with a synthetic peptide (KKTFSLSPTVWFLREG) and
generating hybridoma clones using standard protocols. Clones
were selected with a proprietary screening platform. Out of 2,592
candidates, one clone (7H9) demonstrated suitable S1P3-specific
binding. Unless otherwise indicated, all studies were performed
using antibody that was purified from ascites fluid by protein A/G
affinity chromatography (Thermo Fisher Scientific, Rockford, IL,
USA).
Cell Lines and Tissue Culture
HEK293 (CRL-1573), RH7777 (CRL-1601), C6 (CCL-107),
and MCF7 (HTB-22) cells were obtained from American Type
Culture Collection (ATCC). All cell lines were grown as
monolayers in humidified incubators at 37uC with 5% CO2. Cells
were cultured in DMEM, 25mM D-glucose, 4mM L-glutamine,
1 u/ml penicillin, 1 mg/ml streptomycin, 10% fetal bovine serum
(Invitrogen, Carlsbad, CA, USA).
Immunocytochemistry
For all studies involving immunolabeling, cells were cultured on
collagen-coated coverslips (cat #08-115, Millipore, Billerica, MA,
USA), fixed with 4% paraformaldehyde, incubated overnight with
mouse monoclonal anti-V5 (cat #R960-25, Invitrogen, Carlsbad,
CA, USA) diluted 1:500 in blocking solution (phosphate buffered
saline (PBS)/2.5% BSA/0.3% Triton X-100), then incubated with
Cy3-anti-mouse (cat #AP192C, Millipore, Billerica, MA, USA)
diluted to 1 mg/ml in blocking solution.
Arrestin Translocation
Enhanced green fluorescent protein (EGFP) was cloned in
frame to the C-terminus of full length human b-arrestin in vector
pcDNA3.1 to generate a b-arrestin-EGFP fusion protein expres-
sion construct. Epitope-tagged S1P3 was generated by amplifica-
tion of S1P3 from cDNA derived from MCF7 breast cancer cells
(cat #HTB-22, ATCC) by polymerase chain reaction, and cloning
into pcDNA3.1?V5-His TOPO (cat #K4800-01, Invitrogen,
Carlsbad, CA, USA) per protocol. These constructs were co-
transfected into HEK293 cells with Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA, USA) per protocol. Cells were incubated in
serum-free media 4 to 16 hours prior to stimulation with S1P.
Cells were treated with 1mM S1P or BSA for 15 minutes, fixed
and processed for immunocytochemistry as described above, and
visualized by fluorescence microscopy. Expression of S1P3 was
verified in all cells before capturing images of GFP localization.
Ca
2+ Imaging
Changes in intracellular [Ca
2+] were determined using the
ratiometric calcium indicator dye Fura-2. RH7777 cells were
transfected with an S1P3-EGFP fusion expression construct,
cultured on collagen-coated coverslips, loaded with Fura-2
acetoxymethyl ester (Fura-2/AM; 8mM) in the presence of
1.5 mM pluronic acid F-127, and incubated for 30–45 min at
room temperature in the dark in DMEM. Coverslips were then
washed with PBS and secured to the bottom of a laminar flow
perfusion chamber RC-25 (Warner Instrument Corporation) with
vacuum grease. Cells were selected for absence or presence of
S1P3 expression based on EGFP fluorescence. S1P was prepared
as described above and applied with a micropipette. Images of
Fura-2-loaded cells with the excitation wavelength alternating
between 340 nm and 380 nm were captured with a cooled CCD
camera every ,4 sec. The ratio of fluorescence intensity emitted
after excitation at 340 nm and 380 nm (F340/F380) was
calculated (MetaFluor, Molecular Devices). Cells that exhibited
oscillatory fluorescence or elevated F340/F380 ratios (.0.7) prior
to S1P stimulation were eliminated from analysis. N=23–34.
Camp Measurements
S1P3-EGFP over-expressing cell lines were generated by
transfecting C6 glioma cells with linearized S1P3-EGFP-
pcDNA3.1 using Lipofectamine 200 transfection reagent
(Invitrogen, Carlsbad, CA, USA). Stable transfectants were
selected using 1 mg/ml of geneticin (Invitrogen, Carlsbad, CA,
USA) and clonally expanded. Cells were seeded at 50,000 cells/
well in a 24-well plate, serum-starved overnight, pre-treated
with 7H9 and S1P as indicated, and stimulated with 0.5 mM
forskolin, 0.5 mM 3-isobutyl-1-methylxanthine to elevate basal
cAMP. After a 20 minute incubation, cAMP content was
S1P3-Blocking Antibody
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Ann Arbor, MI) per manufacturer’s instructions.
Systemic Inflammation Model
Systemic inflammation experiments were performed on 6 week-
old, male C57Bl/6J mice obtained directly from The Jackson
Laboratory (Bar Harbor, Maine, USA). Working solutions of
normal mouse IgG (cat # 31202, Thermo Fisher Scientific,
Rockford, IL, USA) and 7H9 were made in PBS at 0.1 mg/ml,
and were administered at 10 ml/g body weight, i.p., 3 times with
the following schedule: 12 hours prior, 15 minutes prior, and
24 hours following LPS administration. LPS was prepared in
a working solution of 0.8 mg/ml in PBS and administered once at
10 ml/g body weight i.p. Mice were monitored continuously for
1 hour, then 3 times/day for 5 days.
Breast Tumor Xenografts
MCF7 human breast tumor cells were cultured until confluence
and the formation of domes, then detached with a rubber
policeman and suspended in 50%PBS/50% Matrigel (cat
#356234, BD Biosciences, San Jose, CA, USA) at ,25 6 10
6
cells/ml. 100ml of cell suspension was delivered subcutaneously
into 6 week-old, female NU/J mice (stock # 002019, The Jackson
Laboratory, Bar Harbor, Maine, USA) under isoflorane anesthe-
sia. Concurrently, a 60-day release estrogen pellet (cat #SE-121,
Innovative Research of America, Sarasota, FL, USA) was
implanted at a second subcutaneous site. Tumor development
was monitored every ,2 days by caliper measurement. Tumor
volume was calculated by length 6width
2.
Histology
Tumors were harvested, cut into pieces ,10 mm in diameter,
fixed in 4% paraformaldehyde overnight, processed and embed-
ded in paraffin using standard techniques, sectioned at 10 mm, and
stained with hematoxylin and eosin. Images were captured with
a 5X objective. Area of necrotic lesions and total tumor area were
determined with Image J software.
Supporting Information
Figure S1 Immunocytochemical analysis of serum from
treated mice demonstrates that 7H9 stably accumulates
in serum. Mice were treated with normal IgG (A-C) or 7H9 (D-
F) at 1 mg/kg, i.p., QOD for 3 weeks, and serum was collected
two days after the last dose. HEK293 cells were transfected with
S1P3-GFP and incubated with diluted serum (1:100). Detection
with a Cy3-anti-mouse IgG reveals that S1P3-reactive antibodies
are present only in 7H9-treated serum at a concentration of 10–
100 mg/ml.
(TIF)
Figure S2 Treatment with 7H9 may improve tamoxifen
efficacy. MCF7 xenograft tumors were established in a small
cohort of nude mice as described in Materials and Methods. (A)
Mean tumor volume was reduced by 7H9 (1 mg/kg, i.p., QOD)
or tamoxifen (5 mg, 60-day release, s.q.) monotherapies, and by
combined treatment. (B) Tumor cell proliferation was evaluated by
immunolabeling with mitotic marker, phospho-histone H3 (EMD
Millipore, Billerica, MA), and counting positive nuclei under 20X
magnification. (C) Area of necrotic lesions was calculated as
described in Materials and Methods. N=3 mice/group, *p,0.05.
(TIF)
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